Pro Share Advisors LLC Coherus Bio Sciences, Inc. Transaction History

Pro Share Advisors LLC

  • $48.7 Billion
  • Q2 2025

A detailed history of Pro Share Advisors LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 21,748 shares of CHRS stock, worth $37,624. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,748
Previous 24,331 10.62%
Holding current value
$37,624
Previous $19,000 21.05%
% of portfolio
0.0%
Previous 0.0%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025
SELL
$0.72 - $1.12 $1,859 - $2,892
-2,583 Reduced 10.62%
21,748 $15,000
Q1 2025

May 08, 2025
SELL
$0.81 - $1.66 $5,673 - $11,626
-7,004 Reduced 22.35%
24,331 $19,000
Q4 2024

Feb 13, 2025
BUY
$0.67 - $1.71 $2,347 - $5,991
3,504 Added 12.59%
31,335 $43,000
Q3 2024

Nov 13, 2024
BUY
$0.99 - $1.8 $6,621 - $12,038
6,688 Added 31.63%
27,831 $28,000
Q2 2024

Aug 13, 2024
SELL
$1.58 - $2.51 $8,721 - $13,855
-5,520 Reduced 20.7%
21,143 $36,000
Q1 2024

May 08, 2024
BUY
$2.02 - $3.14 $6,116 - $9,507
3,028 Added 12.81%
26,663 $63,000
Q4 2023

Feb 14, 2024
BUY
$1.59 - $3.85 $7,145 - $17,301
4,494 Added 23.48%
23,635 $78,000
Q3 2023

Nov 13, 2023
BUY
$3.74 - $5.45 $4,858 - $7,079
1,299 Added 7.28%
19,141 $71,000
Q2 2023

Aug 10, 2023
BUY
$3.79 - $8.3 $7,655 - $16,766
2,020 Added 12.77%
17,842 $76,000
Q1 2023

May 11, 2023
SELL
$5.89 - $10.52 $11,609 - $20,734
-1,971 Reduced 11.08%
15,822 $108,000
Q4 2022

Feb 02, 2023
BUY
$5.69 - $10.07 $7,857 - $13,906
1,381 Added 8.41%
17,793 $140,000
Q3 2022

Nov 04, 2022
BUY
$7.17 - $13.87 $1,892 - $3,661
264 Added 1.63%
16,412 $158,000
Q2 2022

Aug 01, 2022
SELL
$5.86 - $13.23 $36,683 - $82,819
-6,260 Reduced 27.94%
16,148 $117,000
Q1 2022

May 10, 2022
SELL
$10.92 - $16.41 $50,253 - $75,518
-4,602 Reduced 17.04%
22,408 $289,000
Q4 2021

Feb 08, 2022
BUY
$15.81 - $18.99 $12,948 - $15,552
819 Added 3.13%
27,010 $432,000
Q3 2021

Nov 12, 2021
SELL
$12.68 - $17.79 $74,545 - $104,587
-5,879 Reduced 18.33%
26,191 $421,000
Q2 2021

Aug 13, 2021
BUY
$12.95 - $15.41 $56,850 - $67,649
4,390 Added 15.86%
32,070 $444,000
Q1 2021

May 14, 2021
BUY
$14.42 - $21.39 $33,324 - $49,432
2,311 Added 9.11%
27,680 $404,000
Q4 2020

Feb 09, 2021
BUY
$16.56 - $18.94 $93,000 - $106,367
5,616 Added 28.43%
25,369 $441,000
Q3 2020

Nov 13, 2020
SELL
$17.41 - $19.89 $8,147 - $9,308
-468 Reduced 2.31%
19,753 $362,000
Q2 2020

Aug 03, 2020
BUY
$14.43 - $19.16 $99,725 - $132,414
6,911 Added 51.92%
20,221 $361,000
Q1 2020

May 15, 2020
SELL
$11.67 - $22.53 $120,656 - $232,937
-10,339 Reduced 43.72%
13,310 $216,000
Q4 2019

Feb 12, 2020
SELL
$16.33 - $21.37 $37,330 - $48,851
-2,286 Reduced 8.81%
23,649 $426,000
Q3 2019

Nov 12, 2019
BUY
$16.3 - $23.37 $3,097 - $4,440
190 Added 0.74%
25,935 $525,000
Q2 2019

Aug 13, 2019
SELL
$13.1 - $22.1 $44,880 - $75,714
-3,426 Reduced 11.74%
25,745 $569,000
Q1 2019

May 15, 2019
BUY
$8.38 - $15.5 $5,413 - $10,013
646 Added 2.26%
29,171 $398,000
Q4 2018

Feb 14, 2019
SELL
$8.65 - $16.28 $47,410 - $89,230
-5,481 Reduced 16.12%
28,525 $258,000
Q3 2018

Nov 14, 2018
SELL
$14.45 - $20.25 $5,245 - $7,350
-363 Reduced 1.06%
34,006 $561,000
Q2 2018

Aug 13, 2018
BUY
$10.25 - $17.45 $16,799 - $28,600
1,639 Added 5.01%
34,369 $481,000
Q1 2018

May 14, 2018
SELL
$9.1 - $13.7 $38,074 - $57,320
-4,184 Reduced 11.33%
32,730 $362,000
Q4 2017

Feb 14, 2018
BUY
$8.35 - $14.4 $13,852 - $23,889
1,659 Added 4.71%
36,914 $325,000
Q3 2017

Nov 13, 2017
BUY
$11.1 - $14.5 $61,494 - $80,330
5,540 Added 18.64%
35,255 $471,000
Q2 2017

Aug 11, 2017
BUY
N/A
29,715
29,715 $426,000

Others Institutions Holding CHRS

# of Institutions
120
Shares Held
58.2M
Call Options Held
89.3K
Put Options Held
31K
View Full List

About Coherus BioSciences, Inc.

CHRS Quotes by TradingView
  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $134M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email